Beam Therapeutics Inc. (BEAM)
$23.9
Rating:
Recommendation:
-
| Symbol | BEAM |
|---|---|
| Price | $23.9 |
| Beta | 1.614 |
| Volume Avg. | 0.85M |
| Market Cap | 1.893B |
| Shares () | - |
| 52 Week Range | 22.52-54.3 |
| 1y Target Est | - |
| DCF Unlevered | BEAM DCF -> | |
|---|---|---|
| DCF Levered | BEAM LDCF -> | |
| ROE | -41.67% | Strong Sell |
| ROA | -23.25% | Sell |
| Operating Margin | - | |
| Debt / Equity | 21.60% | Neutral |
| P/E | -5.62 | Strong Sell |
| P/B | 2.25 | Strong Buy |
Latest BEAM news
About
Download (Excel)Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.